SCHEMBL22729336

SCHEMBL22729336

CN(C)CCNC(=O)CC(C)(C)NC(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 2/20 0.45
CTSS P25774 2/20 0.43
HTT P42858 1/20 0.43
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CTSK P43235 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
KCNA5 P22460 1/20 0.41
TGM2 P21980 1/20 0.41
SYK P43405 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17371252 0.83 MEN1 (0.49) MEN1KMT2ASMN1; SMN2LMNACTSS
SCHEMBL7333270 0.83 MEN1 (0.48) MEN1KMT2ASMN1; SMN2LMNACTSS
SCHEMBL2188218 0.82 SMN1; SMN2 (0.50) MEN1KMT2ASMN1; SMN2LMNACTSS
SCHEMBL2187728 0.82 SMN1; SMN2 (0.45) MEN1KMT2ASMN1; SMN2LMNACTSS
SCHEMBL14772158 0.82 LMNA (0.65) MEN1KMT2ASMN1; SMN2LMNACTSS
SCHEMBL21227021 0.80 HTT (0.57) MEN1KMT2ASMN1; SMN2LMNACTSS
SCHEMBL848606 0.80 SMN1; SMN2 (0.50) MEN1KMT2ASMN1; SMN2LMNACTSS
SCHEMBL2188090 0.79 SMN1; SMN2 (0.52) MEN1KMT2ASMN1; SMN2LMNACTSS
SCHEMBL847723 0.79 KMT2A (0.55) MEN1KMT2ASMN1; SMN2LMNACTSS
SCHEMBL23040932 0.79 MEN1 (0.47) MEN1KMT2ASMN1; SMN2LMNACTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111630058-B Glucopyranosyl derivative and use thereof 广东东阳光药业有限公司 2022-02-15 CN disclosed
US-11186602-B2 Glucopyranosyl derivative and use thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-11-30 US disclosed
US-20210054013-A1 GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-02-25 US disclosed
EP-3747892-A1 GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2020-12-09 EP disclosed
CN-111630058-A Glucopyranosyl derivative and use thereof 广东东阳光药业有限公司 2020-09-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11186602-B2 Glucopyranosyl derivative and use thereof SLC5A1, SLC5A2, UGGT1 MEN1 3320/4885KMT2A 2942/4885SMN1; SMN2 3620/4885
US-20210054013-A1 GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF SLC5A1, SLC5A2, UGGT1 MEN1 3320/4885KMT2A 2942/4885SMN1; SMN2 3620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.